[资料]Cochrane Library system review NSCLC 预防性 PCI
这个帖子发布于 19 年零 228 天前，其中的信息可能已发生改变或有所发展。
Cochrane review abstract and plain language summary
This is an abstract and plain language summary of a regularly updated, systematic review prepared and maintained by The Cochrane Collaboration. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
The Cochrane Database of Systematic Reviews 2005 Issue 4
Copyright ?2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer
Lester JF, Coles B, Macbeth FR
Plain language summary
Patients with non-small cell lung cancer have a significant risk of developing tumour spread to the brain (metastases) after their initial potentially curative treatment. So far, four research trials have been published. Unfortunately they included different groups of patients who had different doses of radiotherapy, and different outcomes were measured. None of the trials showed that patients who had received prophylactic radiotherapy to the brain lived longer than those who had not, although fewer of them developed metastases. More research with a larger number of patients is needed.
Abstract
Background
In non-small cell lung cancer (NSCLC), there is a relatively high incidence of brain metastases following radical treatment. At present, the role of prophylactic cranial irradiation (PCI) in this group of patients is not clear.
Objectives
To investigate whether PCI has a role in the management of patients with NSCLC treated with radical intent.
Search strategy
The electronic databases MEDLINE, EMBASE and Cancerlit, along with handsearching of journals, relevant books, and review articles used to identify potentially eligible trials.
Selection criteria
Randomised controlled trials (RCTs) comparing PCI with no PCI in NSCLC patients treated with radical intent.
Data collection and analysis
Four RCTs were reviewed. Due to the small patient numbers, and variations in radiotherapy (RT) dose, no meta-analysis was attempted.
Main results
PCI may reduce the incidence of brain metastases, but there is no evidence of a survival benefit. There is no evidence that any regimen is superior, and the effect of PCI on quality of life (QOL) is not known.
Authors' conclusions
There is insufficient evidence to support the use of PCI in clinical practice. Where possible, patients should be offered entry into a clinical trial.
This is an abstract and plain language summary of a regularly updated, systematic review prepared and maintained by The Cochrane Collaboration. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
The Cochrane Database of Systematic Reviews 2005 Issue 4
Copyright ?2005 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer
Lester JF, Coles B, Macbeth FR
Plain language summary
Patients with non-small cell lung cancer have a significant risk of developing tumour spread to the brain (metastases) after their initial potentially curative treatment. So far, four research trials have been published. Unfortunately they included different groups of patients who had different doses of radiotherapy, and different outcomes were measured. None of the trials showed that patients who had received prophylactic radiotherapy to the brain lived longer than those who had not, although fewer of them developed metastases. More research with a larger number of patients is needed.
Abstract
Background
In non-small cell lung cancer (NSCLC), there is a relatively high incidence of brain metastases following radical treatment. At present, the role of prophylactic cranial irradiation (PCI) in this group of patients is not clear.
Objectives
To investigate whether PCI has a role in the management of patients with NSCLC treated with radical intent.
Search strategy
The electronic databases MEDLINE, EMBASE and Cancerlit, along with handsearching of journals, relevant books, and review articles used to identify potentially eligible trials.
Selection criteria
Randomised controlled trials (RCTs) comparing PCI with no PCI in NSCLC patients treated with radical intent.
Data collection and analysis
Four RCTs were reviewed. Due to the small patient numbers, and variations in radiotherapy (RT) dose, no meta-analysis was attempted.
Main results
PCI may reduce the incidence of brain metastases, but there is no evidence of a survival benefit. There is no evidence that any regimen is superior, and the effect of PCI on quality of life (QOL) is not known.
Authors' conclusions
There is insufficient evidence to support the use of PCI in clinical practice. Where possible, patients should be offered entry into a clinical trial.
